Build on our experience of more than 245 rare disease studies in 96 countries to fulfill your promise of hope to millions around the world.
Successfully navigating the road to developing and delivering pediatric products requires a specialized mix of scientific, therapeutic, regulatory and operational expertise to ensure your pediatric studies are successfully planned and executed.
From the earliest planning stages of clinical development, through launch and real-world assessment, pediatric expertise is key to ensuring you are asking the right questions to meet the specific needs of infants, children and adolescents.
At IQVIA, we are prepared to provide tailored, informed support throughout your journey. We can help
Experts from across IQVIA come together to help you conceptualize and execute your pediatric studies. The group is charged with advising on the conduct of pediatric programs to ensure the right strategy and the right level of oversight, counsel, training and collaboration is applied to your project. Identify the right path to fulfill pediatric safety requirements and deliver a product that meets the unique needs of infants, children and adolescents, from trial environments into their everyday lives.
The RACE for Children Act will have significant impact on cancer drug development. Among all ongoing cancer trials, more than 70% involve RACE-defined molecular target drugs, but only 6.9% appear to include pediatric-age participants, according to a new analysis conducted by the IQVIA Institute.
Build on our experience of more than 245 rare disease studies in 96 countries to fulfill your promise of hope to millions around the world.
Identify the best performing sites for your trial in less time with new machine learning and predictive modeling methods.
Bring trials directly to patients to improve access and engagement, increase quality and shorten timelines.